Clinical Trial Update: Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating eltrombopag for secondary poor graft function after allogeneic hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poor Graft Function

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Poor Graft Function | Phase 2 | Status: UNKNOWN